SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jay silberman who wrote (330)2/22/1997 4:11:00 AM
From: scaram(o)uche   of 6136
 
I feel that individuals who had options expiring today were successful in yanking the issue down. It's very frustrating, but those who rode AGPH in lumps and bumps from 10 to 50 and back down to 30 will recognize it. It's called "if you can't beat them by betting correctly, do it with a well-timed rumor or invented critical issue".

At this point, it's largely an issue of documentation in the NDA. FDA needs to hold the AGPH submission to the same standards as they did those from Merck, Abbott and Roche. Given such lofty requirements, paranoia is a ready tool. Of course, the opposite side of the coin is that the goals _are_ lofty.

As always, a starting point for any questions might be IR at AGPH.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News